Annabel Samimy

Stifel Says Allergan Could Use A Face-Lift, Initiates Coverage With Hold

Endo To Enter A Year Of Recovery Following FDA Request To Pull OPANA ER Off The Market

Stifel Sees A Long Road To Stabilization At Valeant

Endo To Enter A Year Of Recovery Following FDA Request To Pull OPANA ER Off The Market

Stifel Sees A Long Road To Stabilization At Valeant

Report: Valeant More Likely To Sell Drugs Than Business Units

Valeant Perception Has Turned A Corner, Stifel Analysts Say

Report: Valeant More Likely To Sell Drugs Than Business Units

Valeant Perception Has Turned A Corner, Stifel Analysts Say

Some On Wall Street Still Back Valeant

Jazz Pharma Falls After Q4 Sales Miss Street View

Annabel Samimy Recent News

Stifel Reiterates Horizon Pharma As 'Select List' Pick, Sees 'Buying Opportunity In Multiple Misguided Reactions'

Stifel Raises Valeant PT As Co. Continues To Execute Global Expansion Strategy

Firms Bullish On Valeant Following Earnings, Acquisition

UPDATE: Stifel Downgrades Salix Pharmaceuticals As Uncovered Inventories Leaves Many Open Questions

Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover

UPDATE: Stifel Reiterates, Lowers Price Target On Egalet Corp As Filing Delay Is Likely

UPDATE: Stifel Downgrades Allergan as Company is Now on the Defensive

UPDATE: Stifel Reiterates on Aerie Pharmaceuticals as Timelines Are on Track

UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

UPDATE: Stifel Downgrades Corcept Therapeutics, See Gradual Progress with Korlym

UPDATE: Stifel Downgrades Santarus Following SLXP Acquisition

UPDATE: Stifel Upgrades Salix Pharmaceuticals Based on SNTS Deal Accretion

UPDATE: Stifel Raises PT on Perrigo Company on Attractive Long-Term Growth Prospects

UPDATE: Stifel Initiates Coverage on Alcobra as Company Regains Focus in Market

UPDATE: Stifel Initiates Coverage on Aerie Pharmaceuticals on Potential of First-In-Class Products

UPDATE: Stifel Upgrades Zogenix Following Approval of Zohydro

UPDATE: Stifel Nicolaus Raises PT on Jazz Pharmaceuticals Following 2Q13 Revenue Report

UPDATE: Stifel Nicolaus Raises PT on Perrigo Following Elan Acquisition

UPDATE: Stifel Nicolaus Raises PT on Santarus Following GI Physician Survey

UPDATE: Stifel Nicolaus Raises PT on Endo Health Solutions Following Opana ER Setback, Management Reshuffling

UPDATE: Stifel Nicolaus Initiates Jazz Pharmaceuticals at Buy on Multiple Positive Factors